Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 1
1964 1
1967 3
1968 1
1971 1
1972 1
1975 1
1976 1
1977 3
1978 2
1981 1
1982 4
1983 6
1984 4
1985 9
1986 4
1987 5
1988 4
1989 20
1990 14
1991 14
1992 15
1993 20
1994 17
1995 19
1996 15
1997 24
1998 25
1999 31
2000 34
2001 78
2002 81
2003 63
2004 53
2005 59
2006 78
2007 92
2008 85
2009 80
2010 90
2011 99
2012 100
2013 123
2014 134
2015 155
2016 149
2017 138
2018 157
2019 184
2020 200
2021 237
2022 265
2023 271
2024 268
2025 127

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,343 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Uhrqvist
Page 1
Surfeando la ola.
Fronzo C. Fronzo C. J Wound Care. 2020 Nov 1;29(LatAm sup 3):5. doi: 10.12968/jowc.2020.29.LatAm_sup_3.5. J Wound Care. 2020. PMID: 33251963 No abstract available.
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, Picus J, Reichert ZR, Szmulewitz RZ, Tagawa ST, Kuzel TM, Bazzi LA, Daignault-Newton S, Whang YE, Dreicer R, Stephenson RD, Rettig MB, Shevrin D, Gerke T, Chinnaiyan AM, Antonarakis ES. Hussain M, et al. Clin Cancer Res. 2024 Oct 1;30(19):4318-4328. doi: 10.1158/1078-0432.CCR-24-1402. Clin Cancer Res. 2024. PMID: 39115414 Clinical Trial.
Median PFS [95% confidence interval (CI)]: Abi/pred, 8.6 months (m; 2.9, 17), Ola, 14 m (8.4, 20), and Abi/pred + Ola, 39 m [22, not reached (NR)]. There were no G4/5 adverse events; 8/19 patients on Abi/pred treatment crossed over to Ola, and 8/21 vice versa …
Median PFS [95% confidence interval (CI)]: Abi/pred, 8.6 months (m; 2.9, 17), Ola, 14 m (8.4, 20), and Abi/pred + Ola, 39 m [2 …
OLA strategy for ARDS: Its effect on mortality depends on achieved recruitment (PaO(2)/FiO(2)) and mechanical power. Systematic review and meta-analysis with meta-regression.
Modesto I Alapont V, Medina Villanueva A, Del Villar Guerra P, Camilo C, Fernández-Ureña S, Gordo-Vidal F, Khemani R. Modesto I Alapont V, et al. Med Intensiva (Engl Ed). 2021 Dec;45(9):516-531. doi: 10.1016/j.medine.2021.03.001. Med Intensiva (Engl Ed). 2021. PMID: 34839883
CONCLUSIONS: There is no clear benefit of OLA strategy on mortality of ARDS patients, with significant heterogeneity among RCTs. Mortality effect of OLA is mediated by lung recruitment and mechanical power....
CONCLUSIONS: There is no clear benefit of OLA strategy on mortality of ARDS patients, with significant heterogeneity among RCTs. Mort …
cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer.
Liang X, Yang Y, Huang C, Ye Z, Lai W, Luo J, Li X, Yi X, Fan JB, Wang Y, Wang Y. Liang X, et al. J Control Release. 2023 Apr;356:691-701. doi: 10.1016/j.jconrel.2023.03.017. Epub 2023 Mar 23. J Control Release. 2023. PMID: 36933699
Herein, we demonstrated a multifunctional nanoparticle (DDP-Ola@HR), which could simultaneously co-deliver DDP and Olaparib (Ola, DNA damage repair inhibitor) using targeted ligand cRGD peptide modified with heparin (HR) as nanocarrier, enabling the concurrent tackl …
Herein, we demonstrated a multifunctional nanoparticle (DDP-Ola@HR), which could simultaneously co-deliver DDP and Olaparib (Ola …
Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight.
Ferreira V, Folgueira C, Guillén M, Zubiaur P, Navares M, Sarsenbayeva A, López-Larrubia P, Eriksson JW, Pereira MJ, Abad-Santos F, Sabio G, Rada P, Valverde ÁM. Ferreira V, et al. Metabolism. 2022 Dec;137:155335. doi: 10.1016/j.metabol.2022.155335. Epub 2022 Oct 19. Metabolism. 2022. PMID: 36272468 Free article.
METHODS: Wild-type (WT) and PTP1B-KO mice were fed an OLA-supplemented diet (5 mg/kg/day, 7 months) or treated with OLA via intraperitoneal (i.p.) injection or by oral gavage (10 mg/kg/day, 8 weeks). ...Both central and i.p. OLA injections increased UCP-1 and …
METHODS: Wild-type (WT) and PTP1B-KO mice were fed an OLA-supplemented diet (5 mg/kg/day, 7 months) or treated with OLA via in …
[Expression and refolding of OLA protein with peptides derived from sheeppox virus].
Wang Z, Zhao Z, Wu G, Deng Y, Zhu G, Zhao F, Lu Z, Zhang Q. Wang Z, et al. Sheng Wu Gong Cheng Xue Bao. 2022 Jan 25;38(1):139-147. doi: 10.13345/j.cjb.210164. Sheng Wu Gong Cheng Xue Bao. 2022. PMID: 35142125 Free article. Chinese.
The aim of this study was to refold the OvisAries leukocyte antigen (OLA) class protein with peptides derived from sheeppox virus (SPPV) to identify SPPV T cell epitopes. Two pairs of primers were designed based on the published sequence of a sheep major histocompatibility …
The aim of this study was to refold the OvisAries leukocyte antigen (OLA) class protein with peptides derived from sheeppox virus (SP …
On-Line Assessment (OLA) as a preparation for the European Diploma in Anaesthesiology and Intensive Care (EDAIC), a retrospective observational study on the results and the potential impact on the Part-I examination.
Brogly N, Varvinskiy A, Varosyan A, Ateleanu B, Engelhardt W, Geldner G, Madách K, Ringvold EM, Zerafa M. Brogly N, et al. Rev Esp Anestesiol Reanim (Engl Ed). 2022 Oct;69(8):454-462. doi: 10.1016/j.redare.2022.08.006. Epub 2022 Sep 8. Rev Esp Anestesiol Reanim (Engl Ed). 2022. PMID: 36089526
This retrospective observational study evaluated the results of the OLA and its impact on the EDAIC-1 between 2013 and 2019. METHODS: After obtaining the authorisation from the ESAIC Examinations Committee, all the results of candidates registered to OLA and/or EDAI …
This retrospective observational study evaluated the results of the OLA and its impact on the EDAIC-1 between 2013 and 2019. METHODS: …
Study on the Tensile Behavior of Woven Non-Woven PLA/OLA/MgO Electrospun Fibers.
Leonés A, Peponi L, García-Martínez JM, Collar EP. Leonés A, et al. Polymers (Basel). 2023 Oct 3;15(19):3973. doi: 10.3390/polym15193973. Polymers (Basel). 2023. PMID: 37836022 Free PMC article.
The present work deeply studied the mechanical behavior of woven non-woven PLA/OLA/MgO electrospun fibers, efibers, by using Box-Wilson surface response methodology. ...Moreover, we identified 1.5 wt% as the critical amount of MgO, above which the plasticizing effect of …
The present work deeply studied the mechanical behavior of woven non-woven PLA/OLA/MgO electrospun fibers, efibers, by using Box-Wils …
Characterization of lipid composition and diffusivity in OLA generated vesicles.
Schaich M, Sobota D, Sleath H, Cama J, Keyser UF. Schaich M, et al. Biochim Biophys Acta Biomembr. 2020 Sep 1;1862(9):183359. doi: 10.1016/j.bbamem.2020.183359. Epub 2020 May 13. Biochim Biophys Acta Biomembr. 2020. PMID: 32416194 Free PMC article.
In this work, we expand the capabilities of the OLA technique by forming GUVs of tunable binary lipid mixtures of DOPC, DOPG and DOPE. ...We studied the OLA derived GUVs under a range of conditions and compared the results with electroformed vesicles. ...
In this work, we expand the capabilities of the OLA technique by forming GUVs of tunable binary lipid mixtures of DOPC, DOPG and DOPE …
Papa Ola Lokahi.
Reppun JI. Reppun JI. Hawaii Med J. 1990 Nov;49(11):408-9, 420. Hawaii Med J. 1990. PMID: 2279921 No abstract available.
3,343 results